Accelr8 Posts Flat Revenues, Narrowed Loss in Fiscal Q1; Sheds No Light on BACcelr8r Availability

Dec 20, 2006

NEW YORK (GenomeWeb News) — Accelr8 Technology yesterday said fiscal first-quarter revenues were unchanged though net loss decreased 30 percent.

Total receipts for the three months ended Oct. 31 were flat at $86,000.

Accelr8 said net losses declined to $539,000 from $772,000 in the year-ago period.

The company attributed the decline to reduced research expenses for its BACcelr8r bacterial-analysis system, which is being prepared for clinical trials.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Prize for Five

Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.

Sure, Blame the Test

Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.

This Week in Genome Research

In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.

Low Down Syndrome Rates in Iceland

Iceland has nearly eliminated Down syndrome from its population, CBS News reports.

Main menu